Akèy › Leksemi mieloïd egi › Vermont › Burlington
Etid klinik pou Leksemi mieloïd egi nan Burlington, VT
7 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Burlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- University of Vermont and State Agricultural College, Burlington
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- University of Vermont Medical Center, Burlington
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- University of Vermont, Burlington
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Burlington
- Ensifizyans kadyak8 etid
- Kansè (tout kalite)6 etid
- BPCO5 etid
- Kansè nan tete5 etid
- Maladi Parkinson4 etid
- Kansè Poumon ki pa ti selil4 etid
- Kansè pwostat4 etid
- Fibroz sistik4 etid
- Maladi poumon4 etid
- Leukemi4 etid
- Maladi kadyovaskilè4 etid
- Kansè Metastatik4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.